What changed for Gout
A plain English summary of what recently moved in the public data Voxsanity tracks for Gout. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 36 to 37 (+1)
- Trials on record 364 to 362 (-2)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Gout in July 2026. Voxsanity tracks 1 PBS-subsidised medicine for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 52 trials tracked for Gout that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04762498 · results posted 19 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04762498) looked at two different doses of a medicine called pegloticase, given together with another medicine called methotrexate, in people with gout. A total of 54 people entered an initial run-in phase where they took methotrexate alone; 51 of them moved on to receive pegloticase. From there, 25 people were assigned to the lower dose (16 mg of pegloticase plus methotrexate) and 26 to the higher dose (30 mg plus methotrexate). The trial measured how the drug moved through the body (pharmacokinetics) and tracked levels o...
-
NCT05289544 · results posted 6 March 2026
According to the results reported on ClinicalTrials.gov, this trial involved 267 adults who were split into two groups. One group (132 people) took part in a phone-based walking program called "Walk With Ease" straight away, while the other group (135 people) was placed on a delay before joining the same program. The trial was measuring two main things: changes in pain levels, and changes in physical function (specifically, how many times participants could stand up from a chair in 30 seconds). By the end of the study, 109 people in the first group and 115 in the second group had completed the...
-
NCT04746989 · results posted 27 February 2026
According to the results reported on ClinicalTrials.gov, this trial compared two existing medicines — probenecid and allopurinol — and looked at how often people developed dementia over time. The study drew on a very large pool of records, starting with over 8,100 people in the probenecid group and more than 286,000 in the allopurinol group, though the final matched comparison used 8,115 people in each group. The main thing being measured was the rate at which participants received a dementia diagnosis (including Alzheimer's disease, vascular dementia, and several related conditions), expresse...
-
NCT04596540 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04596540) enrolled 153 adults across three groups: 51 received a lower dose of SEL-212 (called SEL-212A), 49 received a higher dose (SEL-212B), and 53 received a placebo (a dummy treatment with no active ingredient). All participants received at least one dose of their assigned treatment. The trial was primarily measuring whether the treatment could bring a substance in the blood called uric acid — which builds up in people with gout — below a target level of 6 mg/dL (milligrams per decilitre) and keep it there for at leas...
-
NCT03934099 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational medicine called LC350189 at three different doses — 50 mg, 100 mg, and 200 mg — compared to a placebo (a dummy treatment with no active ingredient). The trial was measuring levels of uric acid in the blood, specifically a substance called serum uric acid (sUA). High uric acid in the blood is associated with gout. A total of 143 people took part across the four groups, and 128 of them completed the study. The reported data shows that the main thing being measured was the proportion of participants who...
-
NCT04075903 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04075903) enrolled a total of 200 participants who were split into two groups: 135 people in the intervention group and 65 people in a control group. All 200 participants completed the study with no drop-outs recorded. The trial was measuring things related to gout — a type of painful joint condition — and tracked whether participants visited a GP or specialist for gout-related care during the study period. The reported data shows one primary outcome measure: the number of participants in each group who attended an outpat...
-
NCT05007392 · results posted 30 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05007392) enrolled 226 people in the febuxostat group and 225 in the dotinurad group — 451 participants in total. The trial was comparing two medicines used to lower uric acid levels in the blood (high uric acid is associated with gout). The main thing the trial was measuring was how many participants reached a blood uric acid level at or below 6.0 mg/dL (milligrams per deciliter, a standard target level) after 24 weeks of treatment. Around 197–220 participants per group were included in the various analyses, with some dro...
-
NCT03636373 · results posted 27 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled a very small number of people — 3 participants received etanercept (a medicine that targets inflammation) and 2 received triamcinolone acetonide (a corticosteroid injection), giving a total of 5 participants. One person in the etanercept group did not finish the trial. The trial was measuring joint pain levels and how patients and doctors rated the response to treatment in people with an acutely painful joint condition. The reported data shows that the main thing being measured was joint pain intensity at 72 hours af...
-
NCT03905512 · results posted 17 October 2023
According to the results reported on ClinicalTrials.gov, this trial compared two treatments for gout — an investigational treatment called SEL-212 and an existing treatment called KRYSTEXXA. A total of 83 people were assigned to the SEL-212 group and 87 to the KRYSTEXXA group, making 170 participants in all. The trial was primarily measuring how many people in each group had their blood uric acid level (a key marker in gout) kept below a target level of 6 mg/dL for at least 80% of the time across months 3 and 6 of the study. The reported data shows that for the main (primary) outcome — keepin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04087720 · results posted 26 July 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04087720) enrolled 20 people who received a treatment called pegloticase, which is given by infusion. The trial was looking at whether the treatment could lower a substance in the blood called uric acid (high levels of which are linked to gout) to below certain target levels, and also whether participants reported changes in pain and day-to-day functioning over 24 weeks. Fifteen of the 20 participants completed the study, and five did not. The reported data shows that for the main outcome — the proportion of participants...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04067492 · results posted 25 July 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 47 people across six groups to test different doses of an investigational treatment called RPH (at 4 mg, 20 mg, 40 mg, 80 mg, and 160 mg doses) compared with a known anti-inflammatory gel, Voltaren® (diclofenac). The trial was measuring changes in joint pain, swelling, tenderness, and redness over time, with the main focus being how much joint pain changed after 72 hours of treatment. Pain was measured using a 100 mm scale where 0 meant no pain at all and 100 meant the worst pain imaginable. Most participants complete...
-
NCT03994731 · results posted 16 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03994731) enrolled 152 adults with gout who had not responded well to standard treatments. Participants were split into two groups: 100 people received the drug pegloticase together with methotrexate (a medicine sometimes used to suppress the immune system), and 52 people received pegloticase together with a placebo (a dummy pill with no active ingredient). The trial's main goal was to measure how many people in each group were able to keep their blood uric acid level — the substance that builds up and causes gout — below...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02959918 · results posted 14 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02959918) enrolled a total of 152 participants across 14 different treatment groups. The trial was testing two investigational treatments for gout — SEL-037 (also called pegadricase, given on its own) and SEL-212 (a combination of SEL-037 and another drug called SEL-110, given at various doses and schedules). Participants received up to five monthly intravenous (drip) infusions. The trial was primarily looking at how many people in each group experienced serious unwanted health events during treatment. It also measured how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02579096 · results posted 11 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 940 people in total — 468 in one group and 472 in the other. It was a two-treatment crossover study, meaning participants in one group took allopurinol (a gout medicine) for the first part of the trial, then switched to a dummy version of febuxostat (another gout medicine), while the other group did the reverse. The trial was looking at gout — a painful condition caused by uric acid build-up in the joints — and the main thing it was measuring was how many people experienced at least one gout flare (a sudden, painful a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03303989 · results posted 10 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03303989) enrolled 35 adults in total — 24 in a group receiving pegloticase (a gout medication given by infusion) combined with mycophenolate mofetil (MMF, an immune-suppressing tablet), and 11 in a group receiving pegloticase combined with a placebo (an inactive tablet). The trial was measuring how many participants could bring their blood uric acid level down to 6 milligrams per deciliter (mg/dL) or lower — a commonly used target in gout management — and keep it there over 12 weeks. Most participants finished the study:...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03226899 · results posted 4 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03226899) enrolled 242 people with gout — 118 in a group that received a placebo (a dummy tablet) alongside a standard gout medicine called a xanthine oxidase inhibitor (XOI), and 124 in a group that received lesinurad (an additional gout medicine) also alongside a XOI. The trial's main goal was to measure how many participants reached a blood uric acid level below 6.0 mg/dL — a commonly used target level in gout management — after six months of treatment. The reported data shows that none of the participants were recorded...
-
NCT01431638 · results posted 19 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT01431638) enrolled 397 people in total — 133 in the Canakinumab pre-filled syringe group, 132 in the Canakinumab lyophilizate (a powder form) group, and 132 in the Triamcinolone Acetonide (a steroid injection) group. The trial was measuring how often unwanted medical events (called adverse events) occurred across the three groups, and also tracked things like how often gout flares happened again, and how participants rated their pain over time. The reported data shows that the primary thing being counted — the number of p...
-
NCT01470989 · results posted 9 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT01470989) enrolled 456 people in total — 227 received a single injection of canakinumab (150 mg) and 229 received a single injection of triamcinolone acetonide (40 mg), a steroid commonly used for gout flares. The trial followed participants across a core study period and up to three extension periods over a longer timeframe. The main thing the trial was measuring was the rate of unwanted medical events (called adverse events), serious adverse events, and deaths, expressed as how often these occurred per 100 years of combi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02287818 · results posted 28 October 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02287818) involved two groups of participants: 60 people received a placebo (a dummy treatment with no active ingredient) and 67 people received a medicine called AC-201. The trial was measuring how many people in each group reached a blood uric acid level below 6.0 mg/dL — uric acid is a substance naturally found in the blood, and this particular level is a commonly used target in gout-related research. Not everyone completed the study: 53 out of 60 in the placebo group and 54 out of 67 in the AC-201 group finished. The...
-
NCT01472692 · results posted 16 December 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01472692) compared a medicine called febuxostat against a placebo (a dummy treatment with no active ingredient) in two groups of participants. The trial was measuring two things: changes in 24-hour blood pressure readings and changes in pulse wave velocity (a measure of how stiff the arteries are, where a higher reading can suggest stiffer blood vessels). However, the reported data shows that the number of participants who started, completed, or did not complete the study was recorded as zero for both groups, which suggest...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02790463 · results posted 12 November 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02790463) involved two groups of people being monitored for gout management. One group received "usual care" (782 participants) and the other received an "intervention" (681 participants). The trial was measuring two things: how many people reached a target level of uric acid in their blood (uric acid is a substance that, at high levels, is linked to gout), and how many people stuck to their prescribed medicines. The reported data shows that when it came to reaching the target blood uric acid level at one year, 117 out of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02855437 · results posted 28 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 44 people in total (23 in one group and 21 in the other). It was a "crossover" study, meaning everyone tried both methods of reporting gout flares — one group started with an Interactive Voice Response (IVR) phone system and then switched to a smartphone app called RheumPRO, while the other group did it the other way around. The trial was measuring two things: which method people preferred, and how practical (feasible) each method was, judged by how often participants actually completed the weekly check-in questions....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01112982 · results posted 7 August 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 74 people with a confirmed diagnosis of gout. Two participants did not complete the study, leaving 72 who finished. The main thing the trial was measuring was how many of those participants showed signs of a type of ongoing joint inflammation — called synovial pannus (a thickening of the joint lining that can cause damage) — in their most affected joint, which was scanned using an MRI (a detailed medical imaging technique). A smaller group of participants then took a uric-acid-lowering medicine called febuxostat for n...
-
NCT03316131 · results posted 18 July 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 adults in total, split into two groups of 18. It used a "crossover" design, meaning each group received both treatment combinations but in a different order — one group received Treatment A followed by Treatment B, and the other received Treatment B followed by Treatment A. All 36 participants completed the first treatment period, and 35 completed the second (one person in the first group did not finish). The trial was measuring how three medicines — verinurad, febuxostat, and dapagliflozin — affected the level of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01808144 · results posted 30 January 2018
According to the results reported on ClinicalTrials.gov, this trial involved two groups of participants who were each taking a combination of two medicines — febuxostat (80 mg) plus either a lower dose (200 mg) or a higher dose (400 mg) of lesinurad. A total of 97 people started in the lower-dose group and 99 in the higher-dose group. The trial was measuring uric acid levels in the blood (uric acid is a substance that builds up in people with gout) and whether lumps under the skin caused by uric acid build-up, called tophi, fully disappeared over the course of the study period. The reported d...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02279641 · results posted 20 December 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants in total, split into two groups of 6 (referred to as Sequence A and Sequence B). All 12 participants completed the study. The trial was a pharmacokinetic study — meaning it was designed to track how two drugs, RDEA3170 (also known as verinurate) and allopurinol, move through the body when taken alone compared to when taken together. Researchers measured things like how high drug levels rose in the blood, how quickly they peaked, how long they stayed in the body, and how much was passed out in urine. T...
-
NCT01459796 · results posted 18 July 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT01459796) enrolled 220 people in total — 94 in the placebo group (a dummy treatment with no active ingredient) and 126 in the rilonacept 80 mg group. The trial was looking at rilonacept, a medicine being tested for gout, and measured two main things: how often unwanted medical events (called "treatment-emergent adverse events") occurred during or shortly after treatment, and how often participants experienced gout flares (sudden, painful gout attacks) over the course of the study. The reported data shows that, for the mai...
-
NCT00855920 · results posted 28 April 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT00855920) involved 225 people in total, spread across three groups: one group received a placebo (dummy treatment) plus indomethacin (a standard anti-inflammatory medicine); a second group received rilonacept (the medicine being studied) plus indomethacin; and a third group received rilonacept plus a placebo instead of indomethacin. The trial was measuring how much joint pain changed over the first three days of treatment, using a simple 0–4 pain scale where 0 meant no pain and 4 meant extreme pain. Most participants compl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00829829 · results posted 28 April 2017
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called rilonacept in people with gout. A total of 241 people were enrolled across three groups — 80 received a placebo (dummy treatment), 80 received a lower dose of rilonacept (80 mg), and 81 received a higher dose (160 mg). The trial ran for 16 weeks (about four months) and was measuring how often participants experienced gout flares — painful episodes typical of a gout attack — during that time. The reported data shows that, on average, participants in the placebo group had 1.06 gout flares each over t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01654276 · results posted 13 January 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 adults who had both gout and high uric acid levels in the blood (a condition called hyperuricemia). The trial tracked several body measurements over roughly six months. Of the 24 people who started, 18 completed the full study period, while 6 did not finish. The reported data shows the following figures recorded at the end of the study for the group as a whole: average body mass index (BMI, a measure of body weight relative to height) was 33.4 kg/m², and average blood uric acid level was 4.4 mg/dl. Blood creatinin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 52 reported results for Gout
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, gout is currently receiving a moderate level of public research investment from the United States, and encouragingly, that investment has been rising over recent years. This upward trend suggests that researchers and funding bodies see gout as an area worth exploring further, which can mean more studies, more questions being asked, and a growing body of evidence over...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.